119 related articles for article (PubMed ID: 37940698)
1. Correction to: The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
Ramchand SK; Tsai JN; Lee H; Sassana-Khadka G; Jordan M; Ryan S; Leder BZ
Osteoporos Int; 2024 Feb; 35(2):371. PubMed ID: 37940698
[No Abstract] [Full Text] [Related]
2. Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.
Tsai JN; Zhu Y; Foley K; Lee H; Burnett-Bowie SA; Neer RM; Leder BZ
J Clin Endocrinol Metab; 2015 Jul; 100(7):2718-23. PubMed ID: 25933031
[TBL] [Abstract][Full Text] [Related]
3. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
4. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2008 Feb; 49(1):119-28. PubMed ID: 18306478
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women.
Um MJ; Cho EA; Jung H
J Menopausal Med; 2017 Apr; 23(1):56-62. PubMed ID: 28523260
[TBL] [Abstract][Full Text] [Related]
9. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.
Mok CC; Ho LY; Leung SMT; Cheung HN; Chen SPL; Ma KM
Bone; 2021 May; 146():115902. PubMed ID: 33631355
[TBL] [Abstract][Full Text] [Related]
10. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
12. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
13. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Morkos M; Mahrous P; Casagrande A; Go MT; Husni H; Hanna M; Goel M; Bedrose S; Li D; Baim S
Endocr Pract; 2022 Oct; 28(10):1078-1085. PubMed ID: 35787466
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density.
Sayed SA; El Wakeel LM; Elseasi AM; Shawki MA
Pharmacotherapy; 2023 Sep; 43(9):904-912. PubMed ID: 37323099
[TBL] [Abstract][Full Text] [Related]
16. Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women.
Liu TC; Hsu CN; Lee WC; Wang SW; Huang CC; Lee YT; Fu CM; Chen JB; Li LC
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259371
[TBL] [Abstract][Full Text] [Related]
17. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
Viggers R; Al-Mashhadi Z; Starup-Linde J; Vestergaard P
Front Endocrinol (Lausanne); 2021; 12():826997. PubMed ID: 35154013
[TBL] [Abstract][Full Text] [Related]
19. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
20. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.
Kim Y; Tian Y; Yang J; Huser V; Jin P; Lambert CG; Park H; You SC; Park RW; Rijnbeek PR; Van Zandt M; Reich C; Vashisht R; Wu Y; Duke J; Hripcsak G; Madigan D; Shah NH; Ryan PB; Schuemie MJ; Suchard MA
Sci Rep; 2020 Jul; 10(1):11115. PubMed ID: 32632237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
